Allied Gold owns several large gold mines in Africa with the Canadian firm describing the all-cash offer as "friendly"; its annual gold output is expected to increase to 25 tonnes by 2029.
Coller Capital is a global secondaries firm with around $50bn in AUM and six Apac offices. EQT's CEO believes Coller's business can double in size in under four years; the PE giant is paying up to $3.7bn. In Japan, EQT has launched a bid for Mamezo.
YP05002, developed by Yao Pharma, is in Phase 1 clinical development in Australia and can potentially help with metabolic diseases; Yao Pharma will receive an upfront payment of $150m for a worldwide licence.
It is the group's largest public IABS issuance to date and its first in the Rule 144A/Reg S format with US onshore investors involved. Clifford Capital's group CEO told FA the deal "reflects the growing interest and appetite in infrastructure returns from institutional investors".